Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this trial is to investigate the pharmacokinetics and pharmacodynamics of
linagliptin (BI 1356) 5 mg administered orally in patients with Type 2 diabetes mellitus of
African American origin.